
POSSIBLE ROLE OF MITOCHONDRIAL
DNA MUTATIONS IN THE ETIOLOGY AND
PATHOGENESIS OF DOWN’S SYNDROME
Arbuzova S* *Corresponding Author: Dr. Svetlana Arbuzova, Interregional Medico-Genetic Center, Central Hospital, Clinic number 1, 57 Artem Street, 83000 Donetsk, Ukraine; Tel: +380-62-2-90-2442; E-mail: s.arbuzova@lb.dn.ua. page: 11
|
DISCUSSION
There is a growing body of evidence supporting the hypothesis that mtDNA mutations are involved in DS etiology, especially where there is familial recurrence. A commonly proposed alternative explanation of DS recurrence is mosaicism, although it cannot account for the familial aggregation of DS with other aneuploidies, and the fact that mosaicism can occur in successive generations [24,25] does not exclude the possibility that mtDNA mutations may cause both full aneuploidy and mosaicism itself.
In families with one affected child, mosaicism of parental lymphocytes or fibroblasts is found in under 5% of cases [26]. It is more common in families with DS recurrence, but even then, the incidence is relatively low. For example, one study found mosaicism in only five out of 22 families, even using DNA analysis which, unlike cytogenetic methods, may detect low-level mosaicism [19]. There are case reports of gonadal mosaicism with a normal chromosome complement in peripheral blood or fibroblasts, but the proportion of families with such errors is not known. However, even a high percentage of trisomic oocytes cannot explain all recurrences: when all are trisomic, half the gametes would be normal. And a serious criticism of all published mosaicism studies is that they did not include controls from unaffected families. Studies on pre-implantation genetic diagnosis show that aneuploidy in oocytes and embryos is not a rare event and it increases markedly with maternal age, being the consequence of both trisomic germ line and further disruption in meiotic division [27].
Although there is evidence for mtDNA involvement in DS pathogenesis, it is widely believed that the oxidative stress in DS is due to a direct gene dosage effect resulting from a 50% increase in the activity of SOD-1. However, examination of the available evidence reveals many contradictions [28].
The association between trisomy 21 and SOD-1 activity is not straight-forward: some DS cases with partial trisomy 21, a translocation or mosaic replication, have normal SOD-1; some cases of partial trisomy 21 without DS have increased SOD-1 [8,29]; and in some DS individuals with partial trisomy 21 the SOD-1 locus is not triplicated [30]. In DS cases, SOD-1 levels vary according to cell or tissue type: in blood cells and fibroblasts activity is generally increased, albeit to a variable extent, while in some individuals who have normal activity and plasma SOD‑1, activity is markedly decreased [29,31-34]. Furthermore, it is far from clear that increased SOD‑1 in DS is a cause of oxidative stress. In one series of DS cases it was found that while SOD‑1 levels fell with age, lipid peroxidation increased [9,12]. An alternative and compelling interpretation of the data on elevated SOD‑1 activity is that it has a protective rather than a harmful effect, since the increase of this scavenger is of benefit for the homeostasis between generated reactive oxygen metabolites and their propagation. In this interpretation SOD‑1 activity in DS is increased as a response to oxidative stress, and unlike unaffected individuals, activity can readily be increased because of the additional copy of the gene. In conclusion, there is more evidence in favor of a role for mtDNA mutations in both DS etiology and pathogenesis than for any of the alternative explanations.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|